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Botulinum toxin – From WMD to therapeutic agent and cosmetic aid
Botulism has long been known but was ﬁ  rst described in the 19th century as a rapidly 
progressing and fatal paralysis following ingestion of blood sausage. It is most notori-
ously associated with the early days of the food canning industry in the beginning of 
the 20th century when many outbreaks occurred particularly in the USA. Food-borne 
botulism remains to this day a cause of regular outbreaks, but the condition can also 
arise from wound infection or enteric bacterial overgrowth. The responsible bacterium, 
Clostridium botulinum, was already isolated and identiﬁ  ed in the 19th century, but 
serious research on the puriﬁ  cation and crystallization of botulinum toxin type A was 
carried out only in the cold war era during the search for biological weapons (Schantz 
and Johnson 1997). Indeed, botulinum toxin became iconic in modern times as one of 
Iraq’s supposed weapons of mass destruction.
Botulinum toxins reduce the presynaptic outﬂ  ow of the neurotransmitter acetylcho-
line at the neuromuscular junction, thereby reducing and ultimately totally blocking 
muscle contraction. The SV2 receptor protein in the presynaptic membrane has been 
recently identiﬁ  ed as the target (Dong et al 2006). Although now notorious as a safe 
and reliable alternative to certain types of cosmetic surgery, real therapeutic use of 
botulinum toxin type A dates back to the 1960s when it was ﬁ  rst used in ophthalmol-
ogy to correct strabismus (Scott et al 1973) and subsequently blepharospasm (Scott 
et al 1985). Indeed, it received FDA approval as long ago as 1989 for the treatment 
of blepharospasm, strabismus, and facial nerve dysfunction, indications which were 
followed by approvals for the treatment of cervical dystonia and axillary hyperhidrosis 
as well as reduction of glabellar lines. In addition to the cosmetic uses (Flynn 2006), 
there are numerous off-label applications including the treatment of sialorrhea, muscle 
control disorders such as limb dystonias and spasticity, and painful disorders like low 
back pain and headache (Cheng et al 2006).
Appearing in this issue of Neuropsychiatric Disease and Treatment are two re-
views of approved and off-label indications for botulinum toxin type A. Stefan Evers 
(2007) reviews placebo-controlled randomized controlled trials (RCTs) in tension-type 
headache and chronic daily headache, and concludes that the majority of trials do not 
suggest that botulinum toxin type A is efﬁ  cacious in the treatment of chronic idiopathic 
headache disorders particularly in chronic tension-type headache. He concedes that 
it is possible that some subgroups of patients with chronic daily headache may ben-
eﬁ  t from long-term treatment with botulinum toxin type A – those who are severely 
impaired and who are not receiving any other type of prophylactic treatment, who 
constitute about 4% of the total patient group, are most likely to beneﬁ  t particularly 
if allodynia is present.
The whole gamut of proven and potential uses of botulinum toxin type A in neu-
rology is reviewed in detail (Ney and Joseph 2007). Clinical uses include the broad 
categories of facial movement disorders, focal neck and limb dystonias, spasticities, 
hypersecretory syndromes, and pain. In many of the potential indications only case 
studies and open label trial are available, but RCTs are becoming the norm as in the 
case of chronic daily headache. However, botulinum toxin type A has become part 
of the daily armamentarium of neurologists and other medical specialists treating 
movement and behavioral disorders. Experimental exploration abounds and perhaps 704
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the most exciting aspect for the neuroscientist is the potential 
neuroprotective effect of botulinum toxin type A in inhibit-
ing enzymes responsible for hippocampal cell death in rats 
(Manno et al 2007). From medieval poison to biological 
weapon to modern therapeutic is quite a transformation, 
and we await further innovative clinical applications with 
considerable curiosity and interest.
References
Cheng CM, Chen JS, Patel RP. 2006. Unlabeled uses of botulinum toxin: 
a review, part 1. Am J Health Syst Pharm, 63:145–52.
Dong M, Yeh F, Tepp WH. 2006. SV2 is the protein receptor for botulinum 
neurotoxin A. Science, 312:592–6.
Evers S. 2007. Review of botulinum toxin type A for the prophylactic 
treatment of chronic daily headache. Neuropsychiatr Dis Treat, 
3:761–4.
Flynn TC. 2006. Update on botulinum toxin. Semin Cutan Med Surg, 
25:115–21.
Manno I, Antonucci F, Caleo M et al. 2007. BoNT/E prevents seizure-
induced activation of caspase 3 in the rat hippocampus. Neuroreport, 
18:373–6.
Ney J, Joseph KR. 2007. Neurologic uses of botulinum neurotoxin type A. 
Neuropsychiatr Dis Treat, 3:785–98.
Schantz EJ, Johnson EA. 1997. Botulinum toxin: the story of its development 
for the treatment of human disease. Perspect Biol Med, 40:317–27.
Scott AB, Kennedy RA, Stubbs HA. 1985. Botulinum A toxin injections as 
a treatment for blepharospasm. Arch Ophthalmol, 103:347–50.
Scott AB, Rosenbaum A, Collins CC. 1973. Pharmacological weakening of 
the extra-ocular muscles. Invest Ophthalmol, 12:924–7.